Reply - 17/08/11
Doi : 10.1016/j.jaci.2006.02.043
David S. Pearlman, MD a, Kerwin Edward, MD b, William E. Berger, MD c, Craig LaForce, MD d, Sudeep Kundu, PhD e, Donald Banerji, MD e
a From the Colorado Allergy and Asthma Centers, PC, Denver
b Clinical Research Institute of Southern Oregon, PC, Medford
c Southern California Research, Mission Viejo
d North Carolina Research, Raleigh
e Sanofi-Aventis US, Inc., Bridgewater, NJ
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: D. Pearlman has consultant arrangements with Sanofi-Aventis, AstraZeneca, MAP Pharmaceuticals, and Altana, and has received grants from pharmaceutically funded clinical research protocols through Colorado Allergy and Asthma Centers, PC, where he is employed. E. Kerwin has received grants for multicenter clinical trials performed for Alone, AstraZeneca, Boehringer Ingelheim, Dey Laboratories, Forest Labs, GlaxoSmithKline, IVAX, Lilly, Merck, Ortho, Pfizer, Roche, Schering-Plough, Sanofi-Aventis, Takeda, Wellstat, and others, and is on the speakers bureau for Pfizer, Sanofi-Aventis, IVAX, Schering-Plough, and GlaxoSmithKline. W. Berger has consultant arrangements, has received grants, and is on the speakers bureau for Schering-Plough, Alcon, Dey, Altana, Verus, Novartis, Genentech, Medpointe, AstraZeneca, Sanofi-Aventis, and Merck. D. Banerji has stock in and is employed by Sanofi-Aventis. S. Kundu is employed by Sanofi-Aventis. The rest of the authors have declared that they have no conflict of interest. |
© 2006
American Academy of Allergy, Asthma and Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 117 - N° 5
P. 1195-1196 - mai 2006 Retour au numéro
Article précédent
- Ciclesonide inhalation aerosol for persistent asthma
- Badrul Alam Chowdhury
- Mycoplasma in severe asthma
- Monica Kraft, Qutayba Hamid
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?